Helicobacter pylori: management in 2013.

Area of Science:

• Gastroenterology
• Infectious Diseases
• Microbiology

Background:

• Helicobacter pylori (H. pylori) infection is a widespread global health concern.
• Treatment strategies must adapt to varying H. pylori antibiotic resistance patterns.
• Effective H. pylori eradication is crucial for patient outcomes, with a target rate of ≥ 80%.

Purpose of the Study:

• To review current therapeutic options for H. pylori infection.
• To highlight treatment choices based on regional antibiotic resistance data.
• To outline first-line, second-line, and rescue therapy recommendations.

Main Methods:

• Review of existing literature on H. pylori treatment regimens.
• Analysis of treatment efficacy based on antibiotic susceptibility.
• Comparison of different therapeutic approaches including triple, quadruple, sequential, and concomitant therapies.

Main Results:

• Triple therapy (proton-pump inhibitor, clarithromycin, amoxicillin/metronidazole) remains a primary option in low-resistance areas.
• Bismuth-containing quadruple therapy is preferred where clarithromycin resistance exceeds 20%.
• Sequential and concomitant therapies offer alternative first- and second-line treatment options, respectively. Levofloxacin-based regimens are effective for second-line treatment.
• Antimicrobial susceptibility testing is recommended for guiding rescue therapy after treatment failure.

Conclusions:

• Treatment selection for H. pylori infection should be guided by local antibiotic resistance prevalence.
• Multiple effective therapeutic regimens exist, including triple, quadruple, sequential, and concomitant therapies.
• Personalized treatment based on susceptibility testing is essential for refractory H. pylori infections.